←
Gabriel Loeb37 posts
Gabriel Loeb avatar

Gabriel Loeb

@LoebLab

Seeking molecular mediators of kidney disease through human genetics, genomics, and novel experimental models. @UCSF, @UCSFNephrology

◷ Joined August 2022▧ 3 Photos and videos
Gabriel Loeb avatar
Gabriel Loeb@LoebLab·Feb 10

Polycystic kidney disease is the most common monogenic cause of kidney failure and affects over 10 million individuals. We've known most PKD is caused by mutations in PKD1 for over 30 years. But how PKD1 prevents disease has remained mysterious, limiting effective therapy.

Post attachment
Gabriel Loeb avatar
Gabriel Loeb@LoebLab·Feb 10

Campaigns to identify and advance small molecules that improve PKD1-PKD2 channel function should be next.

Gabriel Loeb avatar
Gabriel Loeb@LoebLab·Feb 10

Our results suggest that similarly small molecules that improve the trafficking and channel function of PKD1 could treat polycystic kidney disease. Even prior to our manuscript, campaigns to advance small molecules that improve PKD1 trafficking were underway within biotech/pharma

Gabriel Loeb avatar
Gabriel Loeb@LoebLab·Feb 10

Our results are reminiscent of cystic fibrosis. Cystic fibrosis is also a monogenic disease caused by mutations in an ion channel. Distinct small molecule medicines rescue the trafficking and channel function of CFTR dramatically improving many lives.

Gabriel Loeb avatar
Gabriel Loeb@LoebLab·Feb 10

We also found that a subset of pathogenic variants that did not traffic to the primary cilium could be rescued by culture at low temperature. A subset of these temperature sensitive variants had normal ion channel function upon rescue.

Gabriel Loeb avatar
Gabriel Loeb@LoebLab·Feb 10

Surprisingly all pathogenic variants disrupted either trafficking of PKD1 to the primary cilium or function of a PKD1-PKD2 heteromeric ion channel. This human genetic evidence supports a model in which PKD1-PKD2 ion channel function at the primary cilia prevents cysts.

Gabriel Loeb avatar
Gabriel Loeb@LoebLab·Feb 10

We reasoned that we could use human genetic variation in PKD1 to learn how PKD1 prevents cysts. PKD1 pathogenic variants but not benign variants must disrupt molecular functions that restrain cystogenesis. We studied 29 nontruncating pathogenic and benign variants in PKD1.

Anuja Java, MD (she/her) avatar
⟳ Gabriel Loeb retweeted
Anuja Java, MD (she/her)@anuja_java·8 Nov 2025

Incredible session on Genetics in Kidney Disease #KidneyWeek @ASNKidney Outstanding organization & insightful talks by @Vishal_D_Patel #DanielGale #AliGharavi #GabrielLoeb Grateful for the opportunity to present on Genetics of TMA🙏 Thx #ArleneChapman & #EmilieCornecLeGall

🧬Very nice talk about genetics of TMA by @anuja_java at #KidneyWk 👉🏽 Interplay between genetics and triggers 👉🏽Who should we test?

Post attachmentPost attachment
Katalin Susztak avatar
⟳ Gabriel Loeb retweeted
Katalin Susztak@KSusztak·27 Jun 2025

#Whyscience Day51🧠✨A strong finish to our Renal Grand rounds series by a rising star physician scientists ⁦@LoebLab⁩ ⁦@UCSFNephrology⁩ Pushing the frontiers of kidney genomics and single cell omics. The future of nephrology is bright🔆

Post attachment